Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies

IMT-009 Phase 1/2a clinical trial initiation expected in Q4 2022 Preclinical data indicate that IMT-009 restores tumor killing activity with potential for use as monotherapy or in combination with existing therapeutics WALTHAM, Mass., Sept. 21, 2022 ... Biopharmaceuticals, Oncology, FDA Immunitas Therapeutics, immunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news